US regulatory panel backs Cempra’s new antibiotic
Advisors to the US Food and Drug Administration have narrowly backed approval of Cempra’s new antibiotic solithromycin as a treatment for community acquired bacterial pneumonia (CABP).
Read More
Tag: solithromycin
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
